Table 5.
Key clinical trials of immunotherapy combined with targeted therapy.
| Study | Indication | Phase | Treatment (n) | Efficacy endpoints | Grade 3/4 AEs | Reference | ||
|---|---|---|---|---|---|---|---|---|
| RR | PFS | OS | ||||||
| COMBI-i (NCT02967692) | Melanoma | 3 | Spartalizumab + dabrafenib + trametinib (36) | 78% | 23 m | 24-month OS rate 74% | 72% | [272] |
| KEYNOTE-252 (NCT02752074) | Melanoma | 3 | Pembrolizumab + epacadostat (354) | 34% | 4.7 m | 12-month OS rate 74.4% vs. 74.1% | 22% | [273] |
| Pembrolizumab (352) | 32% | 4.9 m | 17% | |||||
| IMspire150 (NCT02908672) | Melanoma | 3 | Atezolizumab + vemurafenib/cobimetinib (256) | 66% | 15.1 m | / | 79% | [138] |
| vemurafenib/cobimetinib (258) | 65% | 10.6 m | / | 73% | ||||
| COLET (NCT02322814) | TNBC | 2 | Atezolizumab + cobimetinib + chemotherapy (32) | 34.4% | 3.8 m | 11.0 m | / | [139] |
| Cobimetinib + chemotherapy (47) | 38.3% | 5.5 m | 16.0 m | / | ||||
| NCT03082534 | HNSCC | 2 | Pembrolizumab + cetuximab (33) | 45% | 6.5 m | 18.4 m | / | [274] |
| MEDIOLA (NCT02734004) | Breast cancer | 1/2 | Durvalumab + olaparib (34) | 63.3% | 8.2 m | 21.5 m | 32% | [147] |
| PEMDAC (NCT02697630) | Uveal melanoma | 2 | Pembrolizumab + entinostat (29) | 14% | 2.1 m | 13.4 m | 66% | [275] |
| EV-103 (NCT03288545) | Urothelial cancer | 1/2 | Pembrolizumab + enfortumab vedotin (45) | 73.3% | 12.3 m | / | / | [153] |
| HR-NBL1/SIOPEN (NCT01704716) | Neuroblastoma | 3 | IL-2 + dinutuximab beta (206) | / | 5-year EFS rate 57% vs. 53% | 5-year OS rate 62% vs. 63% | / | [140] |
| Dinutuximab beta (200) | / | / | ||||||
| NCT02484404 | Ovarian cancer | 2 | Durvalumab + olaparib (35) | 14% | 3.9 m | / | / | [276] |
| KEYNOTE-162 (NCT02657889) | Ovarian carcinoma | 1/2 | pembrolizumab + niraparib (62) | 18% | 3.4 m | / | / | [148] |